Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors

Gene Therapy

Volumn 3, Issue 10, 1996, Pages 886-891

  Coffin, R S ^a   MacLean, A R ^b   Latchman, D S ^a   Brown, S M ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

HSV1 ICP34.5 deletion mutant vectors

Indexed keywords

BETA GALACTOSIDASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CENTRAL NERVOUS SYSTEM; DELETION MUTANT; EXPRESSION VECTOR; FOOT PAD; GENE EXPRESSION; GENE TARGETING; HERPES SIMPLEX VIRUS 1; MARKER GENE; MOUSE; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RECOMBINANT GENE; SPINAL GANGLION; VIRUS MUTANT; VIRUS TITRATION;

ANIMALS; BETA-GALACTOSIDASE; BRAIN; GANGLIA, SPINAL; GENE DELETION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MICE, INBRED BALB C; VIRAL PROTEINS;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1;

EID: 0029909474     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Glorioso JC, Coins WF, Fink DJ. Herpes simplex virus-based vectors. Semin Virol 1992; 3: 265-276.
2. Coffin RS, Latchman DS. Herpes simplex virus-based vectors. In: Latchman DS (ed). Genetic Manipulation of the Nevous System. Academic Press: London, 1996, pp 99-114.
3. Leib DA, Olivo PO. Gene delivery to neurons: is herpes simplex virus the right tool for the job. BioEssays 1993; 15: 547-554.
4. Ace C et at. Construction and characterisation of a herpes simplex virus type 1 mutant unable to transinduce immediate early gene expression. J Virol 1989; 63: 2260-2269.
5. McFarlane M, Daksis JI, Preston CM. Hexamethylene bisacetamide stimulates herpes-simplex virus immediate early gene expression in the absence of trans-induction by VMW65.J Gen Virol 1992; 73: 285-292.
6. Steiner I et al. A herpes simplex virus type 1 mutant containing a nontransducing VMW65 protein establishes latent infection in vivo in the absence of viral replication and reactivates efficiently from explanted trigeminal ganglia. J Virol 1990; 64: 1630-1638.
7. Eizenberg O et al. Linear dimeric interleukin-2 obtained by the use of a defective herpes simplex viral vector: conformation-activity relationship. Mol Br Res 1994; 26: 156-162.
8. Federoff HJ et al. Expression of nerve growth factor in rivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia. Prof Natl Acad Sci USA 1992; 89: 1636-1640.
9. Geller AI et al. Long-term increases in neurotransmitter release from neuronal cells expressing a constitutively active adenylate cyclase from a herpes simplex virus type 1 vector. Proc Natl Acad Sci USA 1993; 90: 7603-7607.
10. Geschwind MD et al. Transfer of the nerve growth factor gene into cell lines and cultured neurons using a defective herpes simplex virus vector. Mol Br Res 1994; 24: 327-335.
11. Ho DY, Mocarski ES, Sapolsky RM. Altering central nervous system physiology with a defective herpes simplex virus vector expressing the glucose transporter gene. Proc Natl Acad Sci USA 1993; 90: 3655-3659.
12. Verhaagen J et al. Expression of growth-associated protein B-50/GAP43 via a defective herpes-simplex virus vector results in profound morphological changes in non-neuronal cells. Mol Br Res 1994; 26: 26-36.
13. During MJ et al. Long-term behavioral recovery in Parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 1994; 266: 1399-1403.
14. Coen DM el al. Thymidine kinase negative herpes-simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci USA 1989; 86: 4736-4740.
15. Goldstein DJ, Weller SK. Herpes-simplex virus type-1-induced ribonucleotide reductase-activity is dispensable for virus growth and DNA-synthesis - isolation and characterisation of an ICP6 IacZ insertion mutant. J Virol 1988; 62: 196-205.
16. Chou J, Roizman B. The terminal 'a' sequence of the herpes simplex virus genome contains the promoter of a gene located in the repeat sequences of the L component. J Gen Virol 1986; 57: 629-637.
17. MacLean AR et al. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence related sequences in Glasgow strain 17 between immediate early gene 1 and the 'a' sequence. J Gen Virol 1991; 72: 632-639.
18. L between 0 to 0.02 and 0.81 to 0.83 map units is non-neurovirulent for mice. J Gen Virol 1989; 70: 705-716.
19. - γ34.5 deletion mutant 1716 is avirulent in SCID mice. J Gen Virol 1994; 75: 2059-2063.
20. Chou J, Roizman B. The γ134.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc Natl Acad Sci USA 1992; 89: 3266-3270.
21. Chou J, Roizman B. Herpes simplex virus 1 γ134.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. Proc Natl Acad Sci USA 1994; 91: 5247-5251.
22. Brown SM et al. ICP34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitro. J Gen Virol 1994; 75: 3679-3686.
23. Bolovan CA, Sawtell NM, Thompson RL. ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J Virol 1994; 68: 48-55.
24. Brown SM et al. Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2. J Gen Virol 1994; 75: 2367-2377.
25. Coffin RS et al. Gene delivery to the heart in vivo and to cardiac myocytes and vascular smooth muscle cells in vitro using herpes virus vectors. Gene Therapy 1996; 3: 560-566.
26. Robertson LM, Maclean AR, Brown SM. Peripheral replication and latency reactivation kinetics of the non-neurovirulent herpes simplex virus type 1 variant 1716. J Gen Virol 1992; 73: 967-970.
27. Spivack JG et al. Replication, establishment of latent infection, expression of the latency-associated transcript and expiant reactivation of herpes simplex virus type 1 γ34.5 mutants in a mouse eye model. J Gen Virol 1995; 76: 321-332.
28. Mineta T et al. Attenuated multi-mutated herpes-simplex virus- 1 for the treatment of malignant gliomas. Nature Med 1995; 1: 938-943.
29. MacLean CA et al. Investigation of herpes simplex virus type 1 genes encoding multiply inserted membrane proteins. J Gen Virol 1991; 72: 897-906.
30. Ho DY, Mocarski ES. Herpes simplex virus latent RNA (LAT) is not required for latent infection in the mouse. Proc Natl Acad Sci USA 1989; 86: 7596-7600.
31. Dobson AT et al. A latent, nonpathogenic HSV-1 derived vector stably expresses β-galactosidase in mouse neurons. Neuron 1990; 5: 353-360.
32. Ecob-Prince MS et al. Expression of β-galactosidase in neurons of dorsal root ganglia which are latently infected with herpes simplex virus 1. J Gen Virol 1995; 76: 1527-1532.
33. Lokensgard JR et al. Long-term promoter activity during herpes simplex virus latency. J Virol 1994; 68: 7148-7158.
34. Feldman LT. Problems in the use of herpes simplex virus as a vector. In: Latchman DS (ed). Genetic Manipulation of the Nervous System. Academic Press: London, 1996, pp 127-134.
35. Wolf JH, Deshmane SL, Fraser NW. Herpes virus vector gene transfer and expression of β-glucuronidase in the central nervous system of MPS VII mice. Nat Genet 1992; 1: 379-384.
36. Perry LJ, McGeoch DJ. The DNA sequences of the long repeat region and adjoining parts of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol 1988; 69: 2831-2846.
37. Latchman D. Herpes simplex virus vectors for gene therapy. Mol Bietech 1994; 2: 179-195.
38. Brown SM, Ritchie DA, Subak-Sharpe JH. Genetic studies with herpes simplex virus type 1. The isolation of temperature-sensitive mutants, their arrangement into complementation groups and recombination analysis leading to a linkage map. J Gen Virol 1973; 18: 329-346.